Skip to main content

Anti-Depressant, Pain Treatment Recalled

November 10, 2017

AvKare Inc. is recalling 274 cartons of Duloxetine Delayed-release Capsules USP, 20 mg, 50 capsules (NDC 50268-283-15), due to the possibility of slightly elevated levels of phthalic acid in the drugs, according to the November 8, 2017, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects lot 18103, which has a November 2018 expiration. Cartons from the lot were distributed to locations across the United States.

Related Content
Stepped Care For PTSD Cost-Effective After Major Hurricanes
Narrow Networks Hinder Mental Health Care Access

AvKare Inc. initiated the voluntary recall October 6, 2017. On October 27, 2017, the FDA designated it Class II. The classification suggests use of the affected capsules could cause temporary or reversible adverse effects. The likelihood of serious harm, however, is remote.

The prescription serotonin and norepinephrine reuptake inhibitor (SNRI), Duloxetine Delayed-release Capsules, are indicated for the treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, and chronic musculoskeletal pain.

Jolynn Tumolo

For more articles like this, visit the Psychiatry Resource Center

For more Pharmacy Learning Network articles, visit the homepage

To learn about Pharmacy Learning Network Live meetings, click here

Back to Top